A comprehensive study of SARS-CoV-2 main protease (M(pro)) inhibitor-resistant mutants selected in a VSV-based system

Nirmatrelvir was the first protease inhibitor (PI) specifically developed against the SARS-CoV-2 main protease (3CL(pro)/M(pro)) and licensed for clinical use. As SARS-CoV-2 continues to spread, variants resistant to nirmatrelvir and other currently available treatments are likely to arise. This stu...

Descripción completa

Detalles Bibliográficos
Autores principales: Costacurta, Francesco, Dodaro, Andrea, Bante, David, Schöppe, Helge, Sprenger, Bernhard, Moghadasi, Seyed Arad, Fleischmann, Jakob, Pavan, Matteo, Bassani, Davide, Menin, Silvia, Rauch, Stefanie, Krismer, Laura, Sauerwein, Anna, Heberle, Anne, Rabensteiner, Toni, Ho, Joses, Harris, Reuben S., Stefan, Eduard, Schneider, Rainer, Kaserer, Teresa, Moro, Stefano, von Laer, Dorothee, Heilmann, Emmanuel
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Cold Spring Harbor Laboratory 2023
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10557589/
https://www.ncbi.nlm.nih.gov/pubmed/37808638
http://dx.doi.org/10.1101/2023.09.22.558628

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10557589/
https://www.ncbi.nlm.nih.gov/pubmed/37808638
http://dx.doi.org/10.1101/2023.09.22.558628

Ejemplares similares